Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Lake Tahoe, California
MINNEAPOLIS, MN, US, Feb. 29, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that Alexander Amalfitano DVM, of Ethos Veterinary Health and Colorado Animal Specialty & Emergency (CASE) presented at the Veterinary Orthopedic Society (“VOS”) annual conference on the completion of the first cohort of dogs in a clinical study, which examined the benefit and tolerability of an intra-articular injection of collagen-elastin hydrogel microparticles (i.e. Spryng™ with OsteoCuhsion™ Technology) into the coxofemoral joint of dogs with osteoarthritis.
“We were pleased to have Dr. Amalfitano present the Spryng clinical study first cohort results at the VOS annual conference as this data demonstrated initial tolerability and further supports our representations regarding the efficacy of this product as a viable option to assist in the management of lamenes in companion animals,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc.
Spryng with OsteoCushion Technology is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
The dogs enrolled in this study had been diagnosed with unilateral or bilateral coxofemoral joint osteoarthritis. Nine dogs have completed the study to date. At day 84, 7 of 9 patients (77.8%) had a greater than 3-point reduction in total CBPI score, and 7 of 9 patients (77.8%) had improved hip extension on goniometry. All 9 patients (100%) had improved visual lameness scores and quality of life assessments In summary, this study demonstrates that Spryng™ may be a viable alternative for medical management of dogs with coxofemoral joint osteoarthritis. To view the abstract of the clinical study presented at the VOS annual conference please visit the following:
About Ethos Veterinary Health
Ethos Veterinary Health is a unique and impactful science-focused animal health company with an emphasis on collaboration, evidence-based decision making, a commitment to the veterinary ethos, and cultivation of passion for what we do. The Company operates 18 hospitals across the United States, with over 400 Doctors of Veterinary Medicine, providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members and collaboration. For more information, visit www.ethosvet.com.
